We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TOASO:BISTTofas Turk Otomobil Fabrikasi A.S. Analysis

Data as of 2026-03-17 - not real-time

TRY 314.75

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Tofas trades at a price that is far above its DCF fair value, reflected in an eye‑catching trailing P/E of roughly 130x while the forward P/E collapses to under 10x on sharply higher projected earnings. Despite a generous dividend yield of about 6.5%, the payout ratio is unsustainably high and free cash flow is deeply negative, raising concerns about the dividend’s longevity. Leverage is also a red flag, with a debt‑to‑equity ratio near 90% and net debt substantially outweighing cash holdings. The recent earnings release noted higher profit and ambitious 2026 targets, but the underlying balance‑sheet stress remains unchanged.
Technically, the stock sits above its 20‑day and 50‑day SMAs and the 30‑day trend is flagged as bullish, yet the MACD has turned bearish and price is edging close to a key support around 278. Volatility is elevated at over 37%**30‑day** and while the beta is low, the Turkish market exposes the share to heightened currency and geopolitical risk. Given the overvaluation, cash‑flow weakness, and mixed technical signals, the outlook calls for caution.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Trailing P/E >130 indicating severe overvaluation
  • Bearish MACD despite overall bullish trend
  • Negative free cash flow and high leverage

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Forward P/E under 10 suggesting earnings upside
  • High dividend yield albeit with sustainability concerns
  • Support level near 278 providing downside cushion

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Structural debt burden and cash‑flow deficits
  • Cyclical exposure of the auto sector in Turkey
  • Potential for earnings growth if 2026 targets are met

Key Metrics & Analysis

Financial Health

Revenue Growth200.20%
Profit Margin2.51%
P/E Ratio130.6
ROE13.73%
ROA0.95%
Debt/Equity89.40
P/B Ratio2.6
Op. Cash FlowTRY2.7B
Free Cash FlowTRY-11274979328

Technical Analysis

TrendBullish
RSI53.9
SupportTRY 278.00
ResistanceTRY 342.50
MA 20TRY 312.39
MA 50TRY 308.46
MA 200TRY 253.17
MACDBearish
VolumeStable
Fear & Greed Index82.13

Valuation

Fair ValueTRY 71.31
Target PriceTRY 397.63
Upside/Downside26.33%
GradeOvervalued
TypeBlend
Dividend Yield6.56%

Risk Assessment

Beta0.24
Volatility37.03%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.